GPh 401

Drug Profile

GPh 401

Alternative Names: GPh-401

Latest Information Update: 18 Dec 2015

Price : $50

At a glance

  • Originator GEROPHARM
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 18 Dec 2015 Preclinical trials in Undefined indication (In adolescents, In infants, In children, In neonates) in Russia (unspecified route) prior to December 2015 (GEROPHARM pipeline, December 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top